Fresco Paula, Oliveira Jorge M A, Kunc Filip, Soares Ana Sofia, Rocha-Pereira Carolina, Gonçalves Jorge, Diniz Carmen
Serviço de Farmacologia, REQUIMTE/FARMA, Faculdade de Farmácia, Universidade do Porto, Rua Aníbal Cunha, 164, P 4050-047 Porto, Portugal.
Neurochem Int. 2007 Jul;51(1):47-56. doi: 10.1016/j.neuint.2007.03.009. Epub 2007 Apr 5.
This work aimed to investigate the molecular mechanisms involved in the interaction of alpha2-adrenoceptors and adenosine A2A-receptor-mediated facilitation of noradrenaline release in rat tail artery, namely the type of G-protein involved in this effect and the step or steps where the signalling cascades triggered by alpha2-adrenoceptors and A2A-receptors interact. The selective adenosine A2A-receptor agonist 2-p-(2-carboxy ethyl) phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680; 100 nM) enhanced tritium overflow evoked by trains of 100 pulses at 5 Hz. This effect was abolished by the selective adenosine A2A-receptor antagonist 5-amino-7-(2-phenyl ethyl)-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo [1,5-c]pyrimidine (SCH 58261; 20 nM) and by yohimbine (1 microM). CGS 21680-mediated effects were also abolished by drugs that disrupted G(i/o)-protein coupling with receptors, PTX (2 microg/ml) or NEM (40 microM), by the anti-G(salpha) peptide (2 microg/ml) anti-G(betagamma) peptide (10 microg/ml) indicating coupling of A2A-receptors to G(salpha) and suggesting a crucial role for G(betagamma) subunits in the A(2A)-receptor-mediated enhancement of tritium overflow. Furthermore, phorbol 12-myristate 13-acetate (PMA; 1 microM) or forskolin (1 microM), direct activators of protein kinase C and of adenylyl cyclase, respectively, also enhanced tritium overflow. In addition, PMA-mediated effects were not observed in the presence of either yohimbine or PTX. Results indicate that facilitatory adenosine A2A-receptors couple to G(salpha) subunits which is essential, but not sufficient, for the release facilitation to occur, requiring the involvement of G(i/o)-protein coupling (it disappears after disruption of G(i/o)-protein coupling, PTX or NEM) and/or G(betagamma) subunits (anti-G(betagamma)). We propose a mechanism for the interaction in study suggesting group 2 AC isoforms as a plausible candidate for the interaction site, as these isoforms can integrate inputs from G(salpha) subunits (released after adenosine A2A-receptor activation; prime-activation), G(betagamma) subunits (released after activation of G(i/o)-protein coupled receptors) which can directly synergistically stimulate the prime-activated AC or indirectly via G(betagamma) activation of the PLC-PKC pathway.
本研究旨在探讨大鼠尾动脉中α2 - 肾上腺素能受体与腺苷A2A受体相互作用介导去甲肾上腺素释放促进作用的分子机制,即参与此效应的G蛋白类型以及α2 - 肾上腺素能受体和A2A受体触发的信号级联相互作用的步骤。选择性腺苷A2A受体激动剂2 - p -(2 - 羧乙基)苯乙氨基 - 5'- N - 乙基羧酰胺腺苷(CGS 21680;100 nM)增强了5 Hz下100个脉冲串诱发的氚溢出。选择性腺苷A2A受体拮抗剂5 - 氨基 - 7 -(2 - 苯乙基)- 2 -(2 - 呋喃基)- 吡唑并[4,3 - e] - 1,2,4 - 三唑并[1,5 - c]嘧啶(SCH 58261;20 nM)和育亨宾(1 μM)消除了该效应。破坏G(i/o)蛋白与受体偶联的药物PTX(2 μg/ml)或NEM(40 μM)、抗G(sα)肽(2 μg/ml)和抗G(βγ)肽(10 μg/ml)也消除了CGS 21680介导的效应,表明A2A受体与G(sα)偶联,并提示G(βγ)亚基在A2A受体介导的氚溢出增强中起关键作用。此外,佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯(PMA;1 μM)或毛喉素(1 μM),分别为蛋白激酶C和腺苷酸环化酶的直接激活剂,也增强了氚溢出。此外,在育亨宾或PTX存在的情况下未观察到PMA介导的效应。结果表明,促进性腺苷A2A受体与G(sα)亚基偶联,这对于释放促进的发生是必不可少的,但不是充分的,需要G(i/o)蛋白偶联(在破坏G(i/o)蛋白偶联、PTX或NEM后消失)和/或G(βγ)亚基(抗G(βγ))的参与。我们提出了一种本研究中相互作用的机制,表明2型腺苷酸环化酶同工型作为相互作用位点的一个合理候选者,因为这些同工型可以整合来自G(sα)亚基(腺苷A2A受体激活后释放;初次激活)、G(βγ)亚基(G(i/o)蛋白偶联受体激活后释放)的输入,它们可以直接协同刺激初次激活的腺苷酸环化酶,或通过PLC - PKC途径的G(βγ)激活间接刺激。